DDrare: Database of Drug Development for Rare Diseases

157. スタージ・ウェーバー症候群
［臨床試験数：8，薬物数：11（DrugBank：4），標的遺伝子数：5，標的パスウェイ数：62］

Searched query = "Sturge-Weber syndrome", "Síndrome de Sturge-Weber"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Cannabidiol; Crema de rapamicina al 1% y excipientes; Crema placebo (excipiente); Topical Rapamycin; Everolimus; Modified Atkins diet; Preservative free artificial tear gel.; Rapamicina tópica al 1% y excipiente; Rapamycin; Sirolimus; Timolol

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03047980 (ClinicalTrials.gov)	January 2017	2/2/2017	Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome	Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome	Sturge-Weber Syndrome	Drug: Sirolimus	Anne Comi, MD	Children's Hospital Medical Center, Cincinnati;Pfizer;National Institutes of Health (NIH);Faneca 66 Foundation;National Institute of Neurological Disorders and Stroke (NINDS)	Active, not recruiting	3 Years	31 Years	All	10	Phase 2;Phase 3	United States
2	NCT02080624 (ClinicalTrials.gov)	January 2011	18/4/2013	Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome	Phase II, Randomized, Triple Blind, Intra-individually Placebo-controlled Clinical Trial to Assess the Efficacy and Safety of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome.	Sturge- Weber Syndrome	Drug: Drug: Topical Rapamycin	Clinica Universidad de Navarra, Universidad de Navarra	NULL	Completed	16 Years	65 Years	Both	23	Phase 2	Spain

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03047980
(ClinicalTrials.gov)

January 2017

2/2/2017

Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome

Sturge-Weber Syndrome

Drug: Sirolimus

Anne Comi, MD

Children's Hospital Medical Center, Cincinnati;Pfizer;National Institutes of Health (NIH);Faneca 66 Foundation;National Institute of Neurological Disorders and Stroke (NINDS)

Active, not recruiting

3 Years

31 Years

All

Phase 2;Phase 3

United States

NCT02080624
(ClinicalTrials.gov)

January 2011

18/4/2013

Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome

Phase II, Randomized, Triple Blind, Intra-individually Placebo-controlled Clinical Trial to Assess the Efficacy and Safety of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome.

Sturge- Weber Syndrome

Drug: Drug: Topical Rapamycin

Clinica Universidad de Navarra, Universidad de Navarra

NULL

Completed

16 Years

65 Years

Both

Phase 2

Spain